Navan Garg

Hypothesis Targeting NTCP and BSEP as a Novel Therapeutic Intervention for the Management of Intra-hepatic Cholestatic Liver Injury

The instance of metabolic dysfunction-associated steatotic liver disease (MASLD) is escalating at a concerning rate, with future estimations indicating a projected prevalence of 33.5% by 2030 worldwide, particularly among the adult population. The major causative factors of MASLD...